Aspazija Sofijanova, Sonja Bojadzieva, Elizabeta Shuperliska, Olivera Jordanova

University Children’s Hospital – Skopje

Abstract:

Introduction:

The aim of this study study was to  investigated whether measurements of serum levels of S100B in asphyxiated full-term newborns may be a useful tool for early detection of postasphyxia brain damage.

Methods:

We included all risk newborns with severe asphyxia, within the first hours after the admission of the delivery were eligible for inclusion in the study. One serum blood sample was obtained from each patient at the 24h post-injury time-point. S100B levels were measured using Electro-Chemi-Luminiscence Immuno Assay-Elecsys 2010-RocheDg. The results were correlated with the presence or absence of neurologic abnormalities at age 3-6 months.

Results:

One hundred  and eightneen newborns were addmited in Intensive Care Unit. The  avarage serum S100B levels for the control group(N=59) was 0.12 microgL(-1) (cut-off point). S100B levels were significantly higher in asphyxiated term newborns N=29; M= 0.64, tham preterm newborns N=30; M=0.18

Conclusion:

S100B protein is good indicator of brain damage in term newborns especially in the first 24h after birth. Longitudinal S100B protein measurements in serum soon after birth are a useful tool to identify which asphyxiated infants are at risk of long-term neurologic sequelae.

Key words: S100B protein, biological marker, brain injury